139 related articles for article (PubMed ID: 31454274)
1. Probability monitoring procedures for sample size determination.
Huang Z; Chow SC
J Biopharm Stat; 2019; 29(5):887-896. PubMed ID: 31454274
[TBL] [Abstract][Full Text] [Related]
2. Innovative design and analysis for rare disease drug development.
Chow SC; Huang Z
J Biopharm Stat; 2020 May; 30(3):537-549. PubMed ID: 32065047
[TBL] [Abstract][Full Text] [Related]
3. Statistical considerations for rare diseases drug development.
Chow SC; Chang YW
J Biopharm Stat; 2019; 29(5):874-886. PubMed ID: 31454299
[TBL] [Abstract][Full Text] [Related]
4. Demonstrating effectiveness or demonstrating not ineffectiveness - A potential solution for rare disease drug product development?
Chow SC; Huang Z
J Biopharm Stat; 2019; 29(5):897-907. PubMed ID: 31454301
[TBL] [Abstract][Full Text] [Related]
5. Sample Size and Data Monitoring for Clinical Trials With Extremely Low Incidence Rates.
Chow SC; Chiu ST
Ther Innov Regul Sci; 2013 Jul; 47(4):438-446. PubMed ID: 30235528
[TBL] [Abstract][Full Text] [Related]
6. Innovative thinking of clinical investigation for rare disease drug development.
Wang P; Chow SC
Orphanet J Rare Dis; 2023 Sep; 18(1):299. PubMed ID: 37740206
[TBL] [Abstract][Full Text] [Related]
7. Unified additional requirement in consideration of regional approval for multiregional clinical trials.
Teng Z; Chen YF; Chang M
J Biopharm Stat; 2017; 27(6):903-917. PubMed ID: 28287339
[TBL] [Abstract][Full Text] [Related]
8. Significance, Errors, Power, and Sample Size: The Blocking and Tackling of Statistics.
Mascha EJ; Vetter TR
Anesth Analg; 2018 Feb; 126(2):691-698. PubMed ID: 29346210
[TBL] [Abstract][Full Text] [Related]
9. Design and analysis of drop-the-losers studies using binary endpoints in the rare disease setting.
Jazić I; Liu X; Laird G
J Biopharm Stat; 2021 Jul; 31(4):507-522. PubMed ID: 34053399
[TBL] [Abstract][Full Text] [Related]
10. An adaptive design to bridge the gap between Phase 2b/3 microbicide effectiveness trials and evidence required for licensure.
Taylor DJ; Grobler A; Abdool Karim SS
Clin Trials; 2012 Aug; 9(4):377-84. PubMed ID: 22610168
[TBL] [Abstract][Full Text] [Related]
11. Flexibility in the FDA approach to orphan drug development.
Hunter NL; Rao GR; Sherman RE
Nat Rev Drug Discov; 2017 Nov; 16(11):737-738. PubMed ID: 28860647
[No Abstract] [Full Text] [Related]
12. Sample size determination for a binary response in a superiority clinical trial using a hybrid classical and Bayesian procedure.
Ciarleglio MM; Arendt CD
Trials; 2017 Feb; 18(1):83. PubMed ID: 28231813
[TBL] [Abstract][Full Text] [Related]
13. The needs of the few.
Nature; 2010 Jul; 466(7303):160. PubMed ID: 20613796
[No Abstract] [Full Text] [Related]
14. Advancing cancer drug development through precision medicine and innovative designs.
Zhang W; Wang J; Menon S
J Biopharm Stat; 2018; 28(2):229-244. PubMed ID: 29173004
[TBL] [Abstract][Full Text] [Related]
15. Approaches to sample size calculation for clinical trials in rare diseases.
Miller F; Zohar S; Stallard N; Madan J; Posch M; Hee SW; Pearce M; Vågerö M; Day S
Pharm Stat; 2018 May; 17(3):214-230. PubMed ID: 29322632
[TBL] [Abstract][Full Text] [Related]
16. A case study of an adaptive design for a clinical trial with 2 doses and 2 endpoints in a rare disease area.
Quan H; Xu Y; Chen Y; Gao L; Chen X
Pharm Stat; 2018 Nov; 17(6):797-810. PubMed ID: 30221446
[TBL] [Abstract][Full Text] [Related]
17. [Sample size calculation in clinical post-marketing evaluation of traditional Chinese medicine].
Fu Y; Xie Y
Zhongguo Zhong Yao Za Zhi; 2011 Oct; 36(20):2904-6. PubMed ID: 22292397
[TBL] [Abstract][Full Text] [Related]
18. Raising orphans: how clinical development programs of drugs for rare and common diseases are different.
Orfali M; Feldman L; Bhattacharjee V; Harkins P; Kadam S; Lo C; Ravi M; Shringarpure DT; Mardekian J; Cassino C; Coté T
Clin Pharmacol Ther; 2012 Aug; 92(2):262-4. PubMed ID: 22739137
[TBL] [Abstract][Full Text] [Related]
19. Operating characteristics of sample size re-estimation with futility stopping based on conditional power.
Lachin JM
Stat Med; 2006 Oct; 25(19):3348-65. PubMed ID: 16345019
[TBL] [Abstract][Full Text] [Related]
20. Sample size determination and treatment screening in two-stage phase II clinical trials via ROC curve.
Huang WS; Chang YI
Pharm Stat; 2018 Sep; 17(5):504-514. PubMed ID: 29722125
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
